ArticleVaccines2025
Next-Generation Influenza Vaccines and the Pandemic Horizon: Challenges, Innovations, and the Road Ahead.
Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in the Development of a Universal Influenza Vaccine.Antibodies (Basel, Switzerland) · 2026Review
- Forecasting Influenza Epidemics and Pandemics in the Age of AI and Machine Learning.Reviews in medical virology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNext-generation influenza vaccines have the potential to overcome the limitations of current seasonal influenza vaccines by providing more efficacious, broader, and longer-lasting protection and enhanced pandemic preparedness. However, their development is constrained by regulatory, financial, and scientific challenges. This study aimed to better understand these barriers and enablers from the perspective of vaccine developers.
methodsWe employed a mixed-methods approach, collecting data through an online survey and follow-up interviews with 17 developers engaged in next-generation influenza vaccine R&D. Thematic analysis was used to identify key scientific, regulatory, and financial challenges, enablers and priorities for advancing development.
resultsDevelopers reported a range of scientific and regulatory challenges, particularly the lack of established correlates of protection and uncertainty around evaluation criteria for novel platforms. High development costs and limited access to sustained funding were consistently cited as key barriers. Developers emphasized the need for clearer regulatory guidance, harmonized approval pathways, and validation of alternative immune markers. Collaborative approaches, including partnerships, consortia, and trial networks, emerged as critical enablers. Most respondents also reported leveraging their influenza vaccine R&D to support COVID-19 vaccine development, underscoring their relevance to broader pandemic preparedness.
conclusionsNext-generation influenza vaccines have the potential to significantly improve both seasonal influenza control and pandemic response. Realizing this potential requires coordinated action to address scientific, regulatory, and financial hurdles. Investment in regulatory innovation, sustainable financing, and collaborative R&D platforms will be essential to accelerate progress and ensure global access to improved influenza vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.